Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease

Nature Nanotechnology

Volumn 10, Issue 1, 2015, Pages 91-98

  Viola, Kirsten L ^a   Sbarboro, James ^a   Sureka, Ruchi ^a   De, Mrinmoy ^b   Bicca, Maíra A ^a,c   Wang, Jane ^a   Vasavada, Shaleen ^a   Satpathy, Sreyesh ^d   Wu, Summer ^d   Joshi, Hrushikesh ^b   Velasco, Pauline T ^a   Macrenaris, Keith ^e   Waters, E Alex ^e   Lu, Chang ^a   Phan, Joseph ^a   Lacor, Pascale ^a   Prasad, Pottumarthi ^f   Dravid, Vinayak P ^b,g   Klein, William L ^a,g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d ILLINOIS MATHEMATICS AND SCIENCE ACADEMY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DIAGNOSIS; MAGNETIC RESONANCE IMAGING; MAGNETISM; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NANOSTRUCTURES; NONINVASIVE MEDICAL PROCEDURES; OLIGOMERS; POSITRON EMISSION TOMOGRAPHY; PROBES; RESONANCE; TISSUE;

ALZHEIMER'S DISEASE; AMYLOID FIBRIL; BRAIN TISSUE; DISEASE MANAGEMENT; MAGNETIC NANOSTRUCTURES; MEMORY LOSS; MOUSE MODELS; NON-INVASIVE DIAGNOSTICS;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN; ANTIBODY; MAGNETIC NANOPARTICLE; OLIGOMER; BIOLOGICAL MARKER; CONTRAST MEDIUM;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTIFACT; BIOCOMPATIBILITY; BRAIN SLICE; BRAIN TISSUE; CELL VIABILITY; CONTROLLED STUDY; DENDRITE; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRODYNAMICS; IMMUNOPRECIPITATION; IN VITRO STUDY; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRE-CLINICAL IMAGING DEVICE; PRIORITY JOURNAL; TEMPORAL CORTEX; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR DIAGNOSIS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; CONTRAST MEDIA; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84926110620     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2014.254     Document Type: Article

References (44)

1. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 10, e47-e92 (2014
2. Georganopoulou D. G., et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 102, 2273-2276 (2005
3. Toledo J. B., Xie S. X., Trojanowski J. Q. & Shaw L. M. Longitudinal change in CSF τ and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126, 659-670 (2013
4. Slemmon J. R., et al. Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects. J. Neurochem. 120, 325-333 (2012
5. Klunk,W. E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Annals Neurol. 55, 306-319 (2004
6. Johnson K. A., et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association. Alzheimers Dement. 9, e1-e16 (2013
7. Terry R. D., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991
8. Nyborg A. C., et al. In vivo and ex vivo imaging of amyloid-beta cascade aggregates with a pronucleon peptide. J. Alzheimer's Dis. 34, 957-967 (2013
9. Klein W. L., Krafft G. A. & Finch C. E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24, 219-224 (2001
10. Lublin A. L. & Gandy S. Amyloid-β oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mount Sinai J. Med. New York 77, 43-49 (2010
11. Ferreira S. T. & Klein W. L. The Aâ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 96, 529-543 (2011
12. Schnabel J. Amyloid little proteins big clues. Nature 475, S12-S14 (2011
13. Mucke L. & Selkoe D. J. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harbor Persp. Med. 2, a006338 (2012
14. Lacor P. N., et al. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 24, 10191-10200 (2004
15. De, M., Chou S. S., Joshi H. M. & Dravid V. P. Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv. Drug Deliv. Rev. 63, 1282-1299 (2011
16. Corot C., et al. in Molecular and Cellular MR Imaging (eds Modo M. M. J. & Bulte J. W. M.) Ch. 4, 59-84 (CRC Press 2007
17. Liu S., et al. A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation characterization and in vivo application. Mol. Pharmaceut. 6, 1074-1082 (2009
18. Serres S., et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl Acad. Sci. USA 109, 6674-6679 (2012
19. Lambert M. P., et al. Monoclonal antibodies that target pathological assemblies of Aβ. J. Neurochem. 100, 23-35 (2007
20. Lambert M. P., Velasco P. T., Viola K. L. & Klein,W. L. Targeting generation of antibodies specific to conformational epitopes of amyloid β-derived neurotoxins. CNS Neurol. Disord. Drug Targets 8, 65-81 (2009
21. Acton P., et al. Anti-ADDL antibodies and uses thereof. US patent 7,811,563 (2010
22. Xiao C., et al. Brain transit and ameliorative effects of intranasally delivered antiamyloid- β oligomer antibody in 5xFAD mice. J. Alzheimer's Dis. 35, 777-788 (2013
23. Gong Y., et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA 100, 10417-10422 (2003
24. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003
25. Chang L., et al. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305-313 (2003
26. Lesne S., et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006
27. Ohno M., et al. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251-260 (2006
28. Mucke L., et al. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000
29. Balducci C., et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AâPP23 transgenic mice. J. Alzheimer's Dis. 21, 1367-1381 (2010
30. Ferretti M. T., et al. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr. Alzheimer Res. 8, 4-23 (2011
31. Takamura A., et al. Extracellular and intraneuronal HMW-AβOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Mol. Neurodegen. 6, 20 (2011
32. Velasco P. T., et al. Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem. Neurosci. 3, 972-981 (2012
33. Oakley H., et al. Intraneuronal â-amyloid aggregates neurodegeneration and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006
34. Barick K. C., et al. Nanoscale assembly of amine-functionalized colloidal iron oxide. J. Magn. Magn. Mater. 321, 1529-1532 (2009
35. Na, H. B., Song I. C. & Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21, 2133-2148 (2009
36. Pinho S. L. C., et al. Fine tuning of the relaxometry of γ-Fe2O3@SiO2 nanoparticles by tweaking the silica coating thickness. ACS Nano. 4, 5339-5349 (2010
37. Prakash A., et al. Bilayers as phase transfer agents for nanocrystals prepared in nonpolar solvents. ACS Nano. 3, 2139-2146 (2009
38. Amstad E., Textor M. & Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale 3, 2819-2843 (2011
39. Tong S., et al. Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett. 10, 4607-4613 (2010
40. Amstad E., et al. Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. Nano Lett. 9, 4042-4048 (2009
41. Palumbo A., Napolitano A., Barone P. & d'Ischia M. Nitrite- and peroxidedependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide induced neurotoxicity in neuronal degeneration. Chem. Res. Toxicol. 12, 1213-1222 (1999
42. Robinson R. MRI probe for amyloid-β oligomers offers potential advantages for detecting Alzheimer's disease. Neurol. Today 12, 20-22 (2012
43. Park J., et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nature Mater. 3, 891-895 (2004
44. Mundt A. P., et al. Targeting activated microglia in Alzheimer's pathology by intraventricular delivery of a phagocytosable MRI contrast agent in APP23 transgenic mice. NeuroImage 46, 367-372 (2009